Category Archives: Corporate
Latest From Corporate
At BIO, new discoveries in research and development are constantly being made by our members. We take pride in the contributions they have made across a diverse range of biotechnology industries, including: healthcare, agricultural, industrial and environmental. As one of the world’s strongest catalysts for innovation, our role within the biotechnology community requires us to reflect on who we are, what we do and how we can better serve our members in future. Biotechnology scientists Read More >
The Center for Advancing Innovation (CAI) announces the launch of the Nanotechnology Startup Challenge for Cancer (NSC2). NSC2 is an open innovation competition designed to bring promising cancer nanotechnology inventions to market.
In case you missed it, The Wall Street Journal published my Letter to the Editor this morning. I make the point that the problem isn’t innovative new treatments from America’s biopharma industry but rather the complex web of health-insurance schemes patients must navigate to access needed medicines. Here is the text of the letter: “Innovative treatments and cures have radically transformed how we treat disease—saving and improving lives and providing tremendous benefits to patients and Read More >
In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug Prices.” The piece is problematic in many respects, but we agree with one of his primary contentions: in discussions about drug prices, value is the real issue. This point was nicely made in a recent Times piece, where it quoted Crystal Bedford, whose five year old daughter, Marley, suffers from a rare genetic disease, Rhizomelic Chondrodysplasia Punctata (RCPD). A treatment Read More >
Even though BIO 2015 in Philadelphia was just two months ago, we already are hard at work getting ready for 2016 and the BIO International Convention in San Francisco (June 6-9, 2016). Our team at BIO is always imagining new ways to improve your experience, to make the most of your time and your meetings and to ensure that you are hearing directly from the key science, policy and investment leaders that allow you to Read More >